Opening Blocked Brain Arteries With a Procedure Versus Medicine Alone After Stroke
Compares a procedure plus medicine with medicine alone for blocked brain arteries.
Plain-language title generated from the registry record
Registry title: Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who had a stroke or mini-stroke from a long-blocked brain artery despite strong medicine. It compares a procedure to reopen the artery plus medicine with medicine alone.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Blocked brain artery (internal carotid, middle cerebral M1, vertebral or basilar artery) that caused a TIA or ischemic stroke despite strong medical treatment. The last event was 14 to 90 days before joining. Occlusion length 15 mm or less. Daily function score (mRS) 0-2.
- Earlier treatment
- Had the event despite aggressive medical management. Refused bypass surgery. Cannot have had bypass surgery or endovascular treatment before.
- Biomarker or test result
- Needs a scan-confirmed blockage, and reduced blood flow behind it (over 30% drop on CT perfusion), poor collateral flow on angiography, or signs of low-flow damage on CT or MRI. Needs at least one risk factor for atherosclerosis.
Main reasons for not taking part
- Severe narrowing (70%-99%) or blockage of other arteries
- Bleeding in the brain, brain tumor or vascular malformation
- Artery disease not caused by atherosclerosis, such as dissection or moyamoya
- Heart-related clot causes such as atrial fibrillation or artificial valve
- Pregnant, perinatal or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07495969, who can take part
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Feng Gao
- Trial code
- NCT07495969
- Record updated
- 27 March 2026
- Original description
A multicenter, randomized, open-label, endpoint-blinded trial to compare the effects of endovascular recanalization plus aggressive medical management with aggressive medical management alone on stroke recurrence and mortality in patients with symptomatic non-acute intracranial artery occlusion.Read full original descriptionShow less
Endovascular Recanalization Versus Aggressive Medical Management Alone for Symptomatic Non-Acute Intracranial Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial
A multicenter, randomized, open-label, endpoint-blinded trial to compare the effects of endovascular recanalization plus aggressive medical management with aggressive medical management alone on stroke recurrence and mortality in patients with symptomatic non-acute intracranial artery occlusion.
Exclusion: Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 90 days after enrollment; Intracranial hemorrhagic diseases such as definite Intracranial tumors, any intracranial vascular malformations, hemorrhagic transformation of infarction, spontaneous intracranial hemorrhage (cerebral parenchymal, subarachnoid, subdural, or epidural) within 30 days; Non atherosclerotic intracranial artery disease: arterial dissection, moyamoya disease or moyamoya syndrome demonstrated by imaging examination, or a definite medical history of autoimmune vasculitis; Known unstable angina or myocardial infarction within the last 6 months; Intolerance or allergic reaction to any treatment-related medication, including aspirin, clopidogrel, heparin, and local or general anesthetics; History of life-threatening allergy to contrast dye; Past history of EC-IC bypass surgery or EVT; Late-stage malignant tumors, cachexia, or other serious diseases and an expected life expectancy of less than 1 year; Any other condition (in the opinion of the site investigator) that inappropriate to participate this study; Severe liver impairment (AST or ALT > 3 times normal, cirrhosis), serum creatinine > 3.0 mg/dl; Severe stenosis (70%-99%) or occlusion of other arteries, or tandem stenosis (70%-99%) that is proximal to the qualifying artery; Evidence of cardioembolic embolism such as atrial fibrillation, prosthetic valve(s), infective endocarditis, mitral stenosis, atrial myxoma, intracardiac clot or vegetation, left ventricular aneurysms, etc; Pregnant, perinatal stage or lactating women.
Clinical inclusion criteria:; Age ranging between 18 and 80 years; Ischemic events (TIA or ischemic stroke) related to the occluded artery, occurring despite aggressive medical management, with the last event occurring within between 14 and 90 days prior to enrollment; The modified Rankin Scale (mRS) score 0-2 at the time of enrollment; At least one risk factor for atherosclerosis; All enrolled patients refused bypass surgery; Signatured informed consent form; Imaging inclusion criteria:; Occlusion of intracranial ICA, M1 segment of MCA, intracranial VA (with contralateral VA hypoplasia or occlusion), or BA, as confirmed by CT angiography (CTA) or digital subtraction angiography (DSA), and the length of the cclusion segment was≤15mm; A decrease of >30% in cerebral blood flow in the territory distal to the target region, as assessed by CT perfusion (CTP); or inadequate collateral compensation indicated by digital subtraction angiography (DSA), defined as an ASITN/SIR collateral grade of 0-2; or evidence of hemodynamic ischemic lesions on CT or MRI; Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 for anterior circulation occlusion, or posterior circulation ASPECTS (pc-ASPECTS) ≥ 6 and pons-midbrain index (PMI) < 3 for posterior circulation occlusion, as demonstrated by CT or MRI; Technical feasibility of endovascular recanalization (ER) in the qualifying artery evaluated by two experienced interventional neuroradiologists.